Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGA CRISPR-sgRNA refers to single guide RNA (sgRNA) sequences designed to target the MGA (MAX Gene Associated) gene using the CRISPR/Cas9 system. In research presented at AACR 2017, these sgRNAs were delivered via lentiviral vectors to silence MGA expression in acute myeloid leukemia (AML) cell lines, such as EOL-1. MGA is a MAX-interacting protein that acts as a transcription factor and potential tumor suppressor by suppressing MYC binding to its targets. Silencing MGA using this CRISPR-sgRNA approach has been shown to enhance cell proliferation and tumor growth in xenograft models, suggesting that loss of MGA function contributes to leukemogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MGA CRISPR-sgRNA.